Puxitatug Samrotecan

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NamePuxitatug Samrotecan
Drug Alias NameAZD-8205AZD8205
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > AZ14170133 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionV-set domain-containing T-cell activation inhibitor 1 inhibitors
TargetsV-set domain-containing T-cell activation inhibitor 1
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisEndometrial Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbThe University Of Texas MD Anderson Cancer Center +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisEndometrial Neoplasms +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A